H.R. 3537Accelerating Access to Critical Therapies for ALS Act

1 recorded action234 of these members are on the 2026 ballotWhat the measure does Read on Congress.gov

Sponsor: Mike Quigley [D-IL-05]
Cosponsors: 331 · 152 Democrats · 98 Republicans
Policy area: Health
Committee: Energy and Commerce Committee
Latest action: Dec 23, 2021 · Became Public Law No: 117-79.

IntroducedMay 25, 2021
Passed the HouseDec 8, 2021
Passed the SenateDec 16, 2021
Sent to the PresidentDec 23, 2021
Became lawDec 23, 2021

What the measure doesCRS summary

Accelerating Access to Critical Therapies for ALS Act

This bill establishes grant programs to address neurodegenerative diseases, such as amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease), and contains other related provisions.

The Department of Health and Human Services (HHS) shall award grants to eligible entities for scientific research utilizing data from expanded access to investigational ALS treatments for individuals who are not otherwise eligible for clinical trials.

The Food and Drug Administration (FDA) shall award grants to public and private entities to cover the costs of research and development of drugs that diagnose or treat ALS and other rare neurodegenerative diseases.

HHS shall also establish the Public-Private Partnership for Neurodegenerative Diseases between the National Institutes of Health, the FDA, and at least one eligible entity (generally, an institution of higher education or a nonprofit organization). The partnership shall support the development and regulatory review of drugs that address ALS and other rare neurodegenerative diseases.

The FDA shall publish on its website a five-year action plan for fostering the development of drugs that improve or extend the lives of people living with rare neurodegenerative diseases.

The Government Accountability Office must report to Congress about the grants provided under this bill, including an analysis of the impact of such grants on research and development of treatments for ALS.

Written by the nonpartisan Congressional Research Service, describing H.R. 3537 as public Law on Dec 23, 2021. It is not the text of the measure; a later amendment may have changed what it does.

How every member votedHouse roll call 415

House Dec 8, 2021

On Motion to Suspend the Rules and Pass, as Amended

Accelerating Access to Critical Therapies for ALS Act

Passed · Two-thirds required

423 Yea 3 Nay 7 not voting

Crossed both parties 3 of 426 voting members broke with their own party: 3 Republicans.

Open the official roll call

How the chamber split

One dot per member. Select a seat or a bar to filter the list.

DemocratsRepublicansFilled: YeaRing: NayGrey: not voting or present

By party select a segment to filter

All members433 members

Democratic220 members

Republican213 members

marks half of the votes cast. A party’s majority is the side most of its voting members took.

Cosponsors331 · 152 Democrats · 98 Republicans

Signing on is not a vote: a member can cosponsor H.R. 3537 and vote against it. 99 signed when it was filed.

Loading the public record

H.R. 3537Accelerating Access to Critical Therapies for ALS Act

What the measure doesCRS summary

How every member votedHouse roll call 415

On Motion to Suspend the Rules and Pass, as Amended

How the chamber split

Cosponsors331 · 152 Democrats · 98 Republicans

H.R. 3537Accelerating Access to Critical Therapies for ALS Act

What the measure doesCRS summary

How every member votedHouse roll call 415

On Motion to Suspend the Rules and Pass, as Amended

How the chamber split

Cosponsors331 · 152 Democrats · 98 Republicans

Who lobbied on H.R. 35373 organizations

Who lobbied on H.R. 35373 organizations